Oramed Pharmaceuticals Inc. (ORMP): history, ownership, mission, how it works & makes money

A Brief History of Oramed Pharmaceuticals Inc. (ORMP)

Company Formation and Early Developments

Oramed Pharmaceuticals Inc. was founded in 2006 and is headquartered in Jerusalem, Israel. The company was created to focus on the development of oral drug delivery systems, particularly for insulin therapy. In its early years, Oramed's primary goal was to revolutionize the management of diabetes by developing an oral alternative to insulin injections.

Key Products and Innovations

Oramed's lead product is ORMD-0801, an oral insulin capsule designed to improve the quality of life for diabetic patients. The product underwent several clinical trials, demonstrating its efficacy and safety. The company also focused on developing other oral formulations for various therapeutic areas.

Clinical Trials and Regulatory Milestones

In December 2016, Oramed announced successful results from its Phase 2 clinical trial of ORMD-0801. The trial included over 80 participants, showcasing statistically significant improvements in glycemic control.

In 2020, Oramed received approval from the FDA to initiate a Phase 3 clinical trial of ORMD-0801. The trial was designed to further validate the effectiveness and safety of the oral insulin formulation in treating Type 2 diabetes.

Financial Performance and Market Presence

As of October 2023, Oramed Pharmaceuticals reported total assets of approximately $29.6 million. The company had cash and cash equivalents of $16.2 million, allowing for continued research and development activities. In the fiscal year 2022, Oramed reported a net loss of $10.5 million with total revenue of $570,000.

Partnerships and Collaborations

In 2021, Oramed entered into a collaboration agreement with Hapyrus Therapeutics to explore new avenues for oral drug delivery technologies, expanding its research capabilities and expertise.

Recent Developments

In September 2023, Oramed announced advancements in its oral insulin delivery system, enhancing formulation stability and bioavailability. The company is also actively pursuing partnerships to broaden its distribution channels worldwide.

Stock Market Information

As of October 2023, Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol ORMP. The stock has seen fluctuations, with a 52-week range between $1.50 and $4.50. Current market capitalization is estimated at around $90 million.

A Who Owns Oramed Pharmaceuticals Inc. (ORMP)

Company Overview

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) is a biopharmaceutical company focused on the development of oral drug delivery systems, with a primary focus on diabetes treatment. The company's lead product is an oral insulin capsule, ORMD-0801, designed to provide a non-invasive alternative to insulin injections.

Major Shareholders

As of the latest filing from September 2023, the following table outlines the major shareholders of Oramed Pharmaceuticals Inc.

Insider Holdings

The following table identifies the ownership of insiders within Oramed Pharmaceuticals Inc.

Stock Performance

As of the end of September 2023, Oramed Pharmaceuticals Inc. has the following stock performance metrics:

• Share Price: $5.20
• Market Capitalization: $73 million
• 52-Week Range: $3.50 - $7.15
• Volume: 150,000 shares traded daily

Analyst Ratings

The analyst ratings provide insight into the market's perspective on Oramed Pharmaceuticals Inc. Here are the latest ratings:

Institutional Ownership Trends

The following statistics represent recent trends in institutional ownership:

• As of Q3 2023, institutional ownership stands at 40% of total shares.
• Increased institutional ownership by 2% compared to Q2 2023.
• Top institutional investors hold approximately 35% of outstanding shares combined.

Oramed Pharmaceuticals Inc. (ORMP) Mission Statement

Company Overview

Oramed Pharmaceuticals Inc. focuses on the development of oral drug delivery systems. The company primarily aims to transform injectable medications into oral formulations. It specializes in diabetes treatment, specifically oral insulin therapies.

Mission Statement

The mission statement of Oramed Pharmaceuticals is to revolutionize the treatment of diabetes through the development of innovative oral delivery systems for insulin and other therapeutic agents. The company is committed to improving patient quality of life and increasing the accessibility of essential medications.

Core Values

• Innovation: Focused on developing breakthrough therapies.
• Integrity: Committed to ethical practices and transparency.
• Quality: Ensuring the highest standards in research and product development.
• Patient-Centric: Prioritizing the needs and well-being of patients.

Financial Performance

As of the latest financial report released on August 31, 2023, Oramed Pharmaceuticals has shown the following key financial metrics:

Research and Development Focus

Oramed Pharmaceuticals is actively pursuing the clinical development of its lead product, ORMD-0801, an oral insulin capsule. The company's R&D investments for the year ending 2023 are projected at approximately $7 million.

Market Potential

The global insulin delivery devices market is expected to reach approximately $17.9 billion by 2028, growing at a CAGR of 10.8%. Oramed’s innovations aim to capture a significant share of this expanding market.

Recent Developments

In June 2023, Oramed announced successful Phase 2 clinical trial results for ORMD-0801, demonstrating significant improvements in glycemic control.

Partnerships and Collaborations

Oramed has established strategic collaborations with various pharmaceutical companies and research institutions to enhance its R&D capabilities and accelerate product development.

Future Goals

• Expand clinical trials for ORMD-0801.
• Increase market outreach for diabetes management solutions.
• Develop additional oral delivery systems for other therapeutic areas.

How Oramed Pharmaceuticals Inc. (ORMP) Works

Overview of Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) is a clinical-stage biopharmaceutical company focused on developing oral drug delivery systems, specifically for the treatment of diabetes and obesity. The company’s lead product candidate is an oral insulin capsule known as ORMD-0801. As of 2023, Oramed is conducting pivotal clinical trials to demonstrate the efficacy and safety of its oral insulin formulation.

Business Model

Oramed operates under a model that emphasizes innovation in drug delivery. The primary focus is on:

• Development of oral pharmaceuticals that can replace injectable therapies.
• Collaboration with research institutions for clinical studies.
• Partnerships with pharmaceutical companies for distribution and commercialization.

Product Pipeline

Oramed’s current product pipeline includes:

Recent Financial Performance

As of the second quarter of 2023, Oramed Pharmaceuticals reported:

• Total Revenue: $0.5 million
• Net Loss: $3.5 million
• Cash and Cash Equivalents: $34.2 million

Market Opportunities

The global insulin market was valued at approximately $28.6 billion in 2022, with Type 2 diabetes therapies expected to grow significantly. The potential market for oral delivery systems is anticipated to capture a significant share of this growth.

Clinical Trial Data

In its recent Phase 2 clinical trials, Oramed demonstrated:

• Reduction in HbA1c levels by an average of 1.5% over 26 weeks.
• Improvement in overall glycemic control without significant hypoglycemia occurrences.

Strategic Partnerships

Oramed has entered into various strategic alliances to enhance its research capabilities and market reach:

• Partnership with a major pharmaceutical company for the distribution of ORMD-0801.
• Collaboration with academic institutions for investigational studies.

Regulatory Approval Status

As of October 2023, Oramed has filed for regulatory approval with:

• The U.S. Food and Drug Administration (FDA).
• The European Medicines Agency (EMA).

Future Outlook

Oramed’s future plans include:

• Initiating Phase 3 trials for ORMD-0801 by Q4 2023.
• Exploring additional indications for oral formulations.

How Oramed Pharmaceuticals Inc. (ORMP) Makes Money

Revenue Streams

Oramed Pharmaceuticals Inc. primarily generates revenue through the development and commercialization of innovative drug delivery systems for diabetes. Their flagship product, ORMD-0801, is an oral insulin capsule currently in various phases of clinical trials.

Product Development

The company focuses on two main product lines:

• ORMD-0801: An oral insulin delivery system for type 2 diabetes.
• ORMD-0901: An oral GLP-1 analogue for type 2 diabetes.

Clinical Trials and Regulatory Milestones

As of the latest reporting period, Oramed has completed Phase 2 clinical trials for ORMD-0801. The results demonstrated a significant reduction in HbA1c levels among participants. The company anticipates entering Phase 3 trials in 2024, which is a pivotal step toward FDA approval.

Financial Performance

For the fiscal year ending August 31, 2023, Oramed Pharmaceuticals reported the following financial data:

Collaborations and Partnerships

Oramed has established strategic collaborations to bolster its financial stability and market reach. As of late 2023, notable partnerships include:

• Collaboration with Israel's Ministry of Health for clinical advancements in oral insulin.
• Partnership with PharmaJet for innovative delivery systems.

Research Grants and Funding

In recent years, Oramed has secured various grants aimed at supporting diabetes research and development:

Market Potential and Future Revenue

The global diabetes drug market is projected to reach approximately $79.2 billion by 2025, with oral insulin representing a significant portion of this growth. Oramed's entry into this market with ORMD-0801 and potential FDA approval could generate substantial revenue, estimated at:

Licensing Agreements

Oramed may also explore licensing agreements for its technology and products, which could provide an additional revenue stream. Current discussions indicate potential interest from several pharmaceutical companies for licensing agreements, estimated to generate: